Natixis Advisors L.P. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 208,015 shares of the medical research company’s stock after selling 30,607 shares during the period. Natixis Advisors L.P.’s holdings in Thermo Fisher Scientific were worth $94,934,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Annapolis Financial Services LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $26,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Thermo Fisher Scientific in the first quarter worth $26,000. ShoreHaven Wealth Partners LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $28,000. Larson Financial Group LLC grew its position in Thermo Fisher Scientific by 38.5% in the fourth quarter. Larson Financial Group LLC now owns 72 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 20 shares during the last quarter. Finally, Oder Investment Management LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $34,000. Institutional investors own 87.17% of the company’s stock.
Several research firms have recently weighed in on TMO. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $535.00 to $575.00 and gave the stock an “overweight” rating in a report on Tuesday, February 2nd. Robert W. Baird reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Monday, May 3rd. UBS Group cut their price objective on Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a research note on Monday, March 29th. Cowen lifted their price objective on Thermo Fisher Scientific from $525.00 to $585.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 2nd. Finally, BTIG Research lifted their price objective on Thermo Fisher Scientific from $540.00 to $590.00 and gave the stock a “buy” rating in a research note on Wednesday, February 3rd. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $534.45.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 29th. The medical research company reported $7.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $6.69 by $0.52. The firm had revenue of $9.91 billion during the quarter, compared to the consensus estimate of $9.69 billion. Thermo Fisher Scientific had a return on equity of 21.35% and a net margin of 17.12%. The company’s quarterly revenue was up 59.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.94 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 19.03 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, April 16th. Investors of record on Tuesday, March 16th were issued a dividend of $0.26 per share. The ex-dividend date of this dividend was Monday, March 15th. This represents a $1.04 annualized dividend and a yield of 0.23%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. Thermo Fisher Scientific’s dividend payout ratio is 8.42%.
In related news, EVP Michel Lagarde sold 34,168 shares of the company’s stock in a transaction on Friday, May 7th. The stock was sold at an average price of $472.60, for a total transaction of $16,147,796.80. Following the completion of the sale, the executive vice president now owns 52,629 shares in the company, valued at $24,872,465.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.44% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More: Do Tariffs Work?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.